January 17, 2024- Premier, Inc. through its ProvideGx® program, has partnered with Amneal Pharmaceuticals, Exela Pharma Sciences and Hikma Pharmaceuticals to supply five vital medications to healthcare providers, helping to meet the immediate and long-term supply needs of drugs necessary for a range of patient care interventions.
With production of both active pharmaceutical ingredients (APIs) and finished product, Amneal will supply potassium phosphate – a key electrolyte drug used to treat or prevent hypophosphatemia or low phosphorus in the blood.
Exela will supply cupric chloride, potassium acetate and zinc chloride – adding to the ProvideGx® electrolyte category portfolio. Premier and member health systems’ investment in Exela, a domestic supplier, has enabled the expansion of Exela’s portfolio to include U.S. Food and Drug Administration (FDA) approvals for new abbreviated drug applications.
Hikma will supply injectable fentanyl – a controlled substance used to prevent pain for short periods of time, usually before anesthesia is administered or immediately after surgical procedures.
Many of these five medications are identified on the U.S. Food and Drug Administration’s (FDA) list of essential medicines – those that are medically necessary to have available at all times in an amount adequate to serve patient needs and in the appropriate dosage forms.